CRISPR: kick-starting the revolution in drug discovery
Gene editing using the CRISPR system has been established as the most powerful tool in the search for new drugs and is now being exploited for therapeutic purposes. Here, Pushpanathan Muthuirulan discusses the promises and wider opportunities of using CRISPR technology to open up the possibility of large-scale screening of drug targets. He also highlights the importance of implementing CRISPR technology into clinical practice for development of next-generation therapeutics and patient-tailored medicine.
THE DRUG discovery process, in which new drug candidates are discovered and evaluated for therapeutic use, has resulted in both promising and life-saving therapies for numerous diseases including inherited genetic disorders and pathogenic infections.1 However, the discovery and testing of a new drug candidate typically takes more than a decade and the total cost associated with drug discovery processes can exceed $1 billion.2 In the United States, the drug discovery process takes an average of 12 years and in excess of $1 billion to develop a new drug.3 Furthermore, only a few drug candidates actually make it to market; the chance of a new drug actually reaching market is only one in 5,000. The high cost and lengthy effort of getting new drugs to market make the drug development process a risky endeavour for pharmaceutical companies, which consequently hinders discovery and development of new therapies. The recent emergence of genome editing technologies and advances in our understanding of human genome sequences have raised hope that direct manipulation of the genome could potentially revolutionise the process of drug discovery and therapeutics.4 In particular, new technologies like CRISPR-Cas9 are key to unlocking potential drug targets and could have a profound impact on modern drug discovery and development.1,5
This content is provided to you for free thanks to the kind support of our sponsor: BMG Labtech, ForteBioI am happy for my details to be shared with the sponsors
13 December 2019
- PJ34 triggers self-destruction of human pancreatic cancer cells
- Vasomotion revealed as potential strategy to treat Alzheimer’s
- Study shows that CRISPR-Cas9 gene editing has a low risk of mistakes
- Root of childhood kidney cancer discovered
- New generation of CAR T cells developed
Read the latest issue
All subscriptions include online membership, giving you access to the journal and exclusive content.SUBSCRIBE TODAYRELATED CONTENT
Open innovation – a collaboration between academia and the pharmaceutical industry to further leverage drug discovery expertise and assets
Leave a Reply
Your email address will not be published. Required fields are marked *
This site uses Akismet to reduce spam. Learn how your comment data is processed.
ADVERTISING & EDITORIAL
- Media Planner
- Publishing Schedule
- Advertising Opportunities
- Advertising Tech Specs
- Author Information
- Advisory Board
- Permission to reuse our content
T: +44 (0)1959 563311
F: +44 (0)1959 563123
Drug Target Review is published by:
Russell Publishing Ltd.
Brasted, Kent, TN16 1NU
© Russell Publishing Limited, 2010-2019. All rights reserved.